Researchers have identified that cancer immunotherapy can lead to colitis due to the activation of the immune system. Certain immunotherapies, such as immune checkpoint inhibitors, boost the immune response against cancer cells but may also inadvertently target healthy cells, including those in the colon. This immune system activation can cause inflammation in the colon, resulting in colitis. Understanding the underlying mechanisms is crucial for improving the safety and efficacy of cancer immunotherapy and managing potential side effects like colitis.
